• WedgeGlobal creative consolidation to Publicis (May 2023, fully consolidated by early 2024) following IPG appointment that lasted only 10 months
• WhyMNC pharma majors in TW: Roche, MSD/Merck, Novartis, AstraZeneca, Sanofi, GSK, Bayer, BMS, Lilly, Takeda. Most run Publicis Health or Ogilvy Health globally. Local TW pharma: TTY Biopharm (4105), Standard Chem (1720), Lotus Pharma — these are TWSE-listed but small ad spenders.

1. W1Global creative consolidation to Publicis (May 2023, fully consolidated by early 2024) following IPG appointment that lasted only 10 months
2. W2Publicis Health (Saatchi Wellness, Digitas Health, Razorfish Health, Heartbeat, Langland) now holds Pfizer global Rx + corporate creative + media
3. W3Vaccine business spend is the primary mass-media surface — separate from Rx HCP work
4. W4Disease-awareness campaigns (unbranded) often briefed to PR/communications shops alongside Publicis Health
5. W5Taiwan adult vaccine policy changes (covered pneumococcal schedule) drive campaign waves

• MNC pharma majors in TW: Roche, MSD/Merck, Novartis, AstraZeneca, Sanofi, GSK, Bayer, BMS, Lilly, Takeda. Most run Publicis Health or Ogilvy Health globally. Local TW pharma: TTY Biopharm (4105), Standard Chem (1720), Lotus Pharma — these are TWSE-listed but small ad spenders.
• LOW. Pfizer global consolidated creative AND media to Publicis Groupe in 2023-2024 (Publicis Health for HCP/professional, Publicis Media for consumer). WPP (Ogilvy Health, GroupM Health) lost the strategic seat in this consolidation. WPP retains some standing relationships at brand/therapy-area level but the central pharma-marketing seat is with Publicis globally. In Taiwan: Publicis Health structures cascade through their Asia network; WPP would need to win at vaccine-business or specific brand level. Plus Pharma is generally a hard category for WPP to lever in Taiwan given Publicis's deep pharma-health specialty infrastructure (Saatchi Wellness, Digitas Health, etc.).
• Adult vaccine schedule policy changes (HCA / CDC announcements)
• Therapy-area-level brand reviews
• Disease-awareness campaign launches (especially with patient organizations)
• Pfizer Taiwan GM / Country Manager changes
• Global Pfizer commercial restructuring announcements

No marketing leadership identified publicly.

Pfizer Taiwan is a top-3 multinational pharma in Taiwan by revenue (alongside Roche, MSD/Merck). Established 1962 — one of the oldest MNC pharma operations in the country. Post-2019 Haleon spin-off, Pfizer Taiwan is now pure-play Rx pharma + vaccines, meaning consumer-facing advertising is SHARPLY LIMITED by Taiwan FDA regulations (Pharmaceutical Affairs Act 藥事法) which restrict Rx drug advertising to medical professionals only. Consumer brand spend is therefore: (a) corporate brand/PR campaigns, (b) disease-awareness campaigns (unbranded — diabetes, cardiovascular, oncology, rare disease awareness), (c) vaccine campaigns (Prevenar adult pneumonia awareness — heavy TW spend), (d) HCP marketing through specialist agencies. Overall paid-media footprint is mid-tier, NOT high — most spend is HCP/medical-channel, not consumer mass media.

No campaigns surfaced in research.

No decision-makers identified.

Pfizer Taiwan reports into Pfizer Asia Cluster (Singapore/Tokyo regional structure varies by business unit). Marketing is organized by therapeutic area (Vaccines, Oncology, Inflammation/Immunology, Internal Medicine, Rare Disease, Hospital) — each with separate budgets, separate KOL networks, separate agency partners. Pfizer Global Medical Affairs and Pfizer Worldwide Commercial Development centralize key creative.